Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
Key takeaways
- (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?
- The Fly reported on June 25 that Guggenheim raised its price target on AMLX to $40 from $30 while reaffirming its Buy rating.
- Just two days prior, on June 23, Amylyx Pharmaceuticals, Inc.
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? Laiba Immad Tue, June 30, 2026 at 8:09 PM GMT+7 2 min read AMLX We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best low-priced pharma stocks on this list.
The Fly reported on June 25 that Guggenheim raised its price target on AMLX to $40 from $30 while reaffirming its Buy rating. The firm also elevated the stock to its Best Idea designation ahead of the anticipated Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia, expected in the third quarter. Guggenheim expressed confidence that the pivotal study will produce favorable outcomes, supporting avexitide's commercial prospects and positioning the therapy to capture a significant share of the estimated $6 billion-plus U.S. post-bariatric hypoglycemia market.
Just two days prior, on June 23, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial evaluating AMX0114 at the European Network to Cure ALS Meeting 2026. The study showed that AMX0114 was not associated with drug-related serious adverse events or serious neurological adverse events in Cohort 1. The safety results support continued testing of higher dose levels in the ongoing multiple ascending dose study. Biomarker assessments, including spectrin breakdown product 145, neurofilament light, and phosphorylated neurofilament heavy, remained close to baseline levels. Cohort 1 evaluated the lowest dose, with future cohorts planned to assess higher doses.